Pharsight

Osmoprep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7687075 SALIX PHARMS Colonic purgative composition with soluble binding agent
Jun, 2028

(4 years from now)

Osmoprep is owned by Salix Pharms.

Osmoprep contains Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate.

Osmoprep has a total of 1 drug patent out of which 0 drug patents have expired.

Osmoprep was authorised for market use on 16 March, 2006.

Osmoprep is available in tablet;oral dosage forms.

The generics of Osmoprep are possible to be released after 22 June, 2028.

How can I launch a generic of OSMOPREP before it's drug patent expiration?
More Information on Dosage

OSMOPREP family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic